LEX Diagnostics Deal, New Product Launches, and Updated 2026 Guidance Highlight Growth Strategy
QuidelOrtho Corporation has reported its financial results for the first quarter of 2026, highlighting a mixed performance shaped by market challenges, strategic investments, and ongoing innovation initiatives. The company, a global leader in in vitro diagnostics, continues to navigate fluctuating demand patterns and geopolitical headwinds while positioning itself for long-term growth.
First Quarter 2026 Overview
For the quarter ended March 29, 2026, QuidelOrtho recorded total revenue of $620 million. While this figure reflects the company’s broad operational footprint, it also underscores the impact of several external and internal factors that weighed on performance during the period.
A key challenge in the quarter was a significantly weaker respiratory season compared to the same period in 2025. This had a pronounced effect on the company’s Point-of-Care segment, which generated $113 million in revenue. This represents a decline of 34% on a reported basis and 35% in constant currency. Respiratory testing demand, which had previously driven strong sales, softened considerably, contributing to the downturn in this segment.
The Labs segment, another major contributor to overall revenue, brought in $353 million. This reflects a decline of 5% as reported and 8% in constant currency. The decrease was primarily attributed to slower distributor sales in China, which the company believes are linked to anticipated changes in pricing guidelines from China’s National Health Security Administration (NHSA). Additionally, ongoing geopolitical tensions in the Middle East disrupted business operations, while the termination of a joint business arrangement with Grifols also impacted revenue.
In contrast, the Immunohematology segment delivered a positive performance. Revenue in this division reached $138 million, representing an 8% increase on a reported basis and 3% growth in constant currency. This growth was driven by strong demand across North America, China, and the Japan and Asia-Pacific (JPAC) regions, demonstrating resilience in certain parts of the company’s portfolio.
Profitability and Earnings
Despite solid contributions from some segments, overall profitability remained under pressure. The company reported a GAAP net loss of $92 million for the quarter, along with a GAAP operating loss of $32 million. Adjusted EBITDA, a key non-GAAP measure used to evaluate operational performance, stood at $109 million.
On a per-share basis, QuidelOrtho reported a GAAP diluted loss of $1.35, while the adjusted diluted loss per share was significantly narrower at $0.04. These figures reflect the ongoing impact of restructuring efforts, operational adjustments, and broader market challenges.
Leadership Perspective
Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho, emphasized that the company’s performance aligned with its preliminary revenue expectations. He noted that the weaker respiratory season, along with disruptions in China and the Middle East, played a major role in shaping the quarter’s results.
At the same time, Blaser expressed confidence in the company’s underlying business strength. He highlighted QuidelOrtho’s continued focus on expanding adjusted EBITDA margins and improving cash flow throughout 2026. According to him, the company remains well positioned to execute on its strategic objectives despite short-term challenges.
Strategic Developments and Innovation
One of the most significant developments during the period was the completion of the acquisition of LEX Diagnostics in April 2026. This acquisition brings an ultra-fast molecular diagnostics platform into QuidelOrtho’s portfolio, enhancing its capabilities in point-of-care testing. The addition is expected to accelerate growth in molecular diagnostics, a key area of focus for the company.
QuidelOrtho also made progress on several product initiatives. Among them was the U.S. launch of its High-Sensitivity Troponin assay, a diagnostic tool designed to improve the detection of cardiac events. In addition, the company began rolling out its VITROS 450 platform in select international markets, expanding its reach and strengthening its global presence.
These innovations are central to the company’s strategy of delivering advanced diagnostic solutions that improve patient outcomes while driving long-term growth. By investing in new technologies and expanding its product portfolio, QuidelOrtho aims to stay competitive in an evolving healthcare landscape.
Updated Full-Year 2026 Guidance
In light of its first-quarter performance and changing market dynamics, QuidelOrtho has updated its financial guidance for the full year 2026. The revised outlook reflects both the challenges encountered in the first quarter and the company’s expectations for the remainder of the year.
The company now projects total revenue in the range of $2.70 billion to $2.75 billion, maintaining the lower end of its previously issued guidance but narrowing the upper range. Adjusted EBITDA is expected to fall between $615 million and $630 million, compared to the earlier range of $630 million to $670 million.
The adjusted EBITDA margin is projected at approximately 23%, slightly below the previously anticipated 23.3%. Adjusted diluted earnings per share are now expected to range from $1.80 to $2.00, down from the earlier estimate of $2.00 to $2.42.
Free cash flow guidance has also been revised downward to a range of $100 million to $120 million, compared to the prior expectation of $120 million to $160 million.
Factors Influencing Outlook
The updated guidance incorporates the anticipated impact of draft pricing guidelines from China’s NHSA for in vitro diagnostics. However, the company noted that it cannot fully assess the implications until the final guidelines and implementation timelines are confirmed.
Additionally, the guidance assumes no significant or prolonged disruption stemming from the ongoing conflict in the Middle East. While current conditions have affected operations, the company does not expect these challenges to escalate materially over the remainder of the year.
QuidelOrtho also acknowledged the inherent difficulty in forecasting certain non-GAAP measures, such as adjusted EBITDA and free cash flow. Due to uncertainties related to potential impairment charges, tax benefits, and other non-recurring items, the company has not provided a reconciliation to comparable GAAP measures.
Investor Communication and Transparency
To provide further insight into its performance and outlook, QuidelOrtho hosted a conference call following the release of its financial results. During the call, management discussed key drivers of the quarter’s performance, strategic priorities, and expectations for the rest of the year.
Presentation materials and a replay of the conference call have been made available on the company’s Investor Relations website, ensuring transparency and accessibility for investors and stakeholders.
Company Overview
QuidelOrtho continues to play a significant role in the global diagnostics industry, with expertise spanning clinical chemistry, immunoassay, immunohematology, and molecular testing. The company’s solutions are designed to deliver fast, accurate, and reliable results across a wide range of healthcare settings, from point-of-care environments to hospitals and laboratories.
By combining innovation with a commitment to improving patient outcomes, QuidelOrtho aims to address some of the most pressing challenges in modern healthcare. Its focus on connecting diagnostic insights with actionable solutions reflects a broader mission to enable better clinical decision-making and enhance the quality of care worldwide.
While the first quarter of 2026 presented several challenges, QuidelOrtho remains focused on executing its long-term strategy. The company’s investments in technology, expansion into new markets, and emphasis on operational efficiency are expected to support future growth.
As the year progresses, key factors to watch will include the finalization of China’s pricing guidelines, the trajectory of global healthcare demand, and the impact of ongoing geopolitical developments. At the same time, the successful integration of LEX Diagnostics and continued product innovation could provide meaningful upside.
Overall, QuidelOrtho’s first-quarter results reflect a company in transition—balancing near-term pressures with long-term opportunities. With a strong foundation and a clear strategic direction, it is working to navigate current uncertainties while building momentum for sustained growth in the years ahead
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
